cipronex 500 mg apvalkotās tabletes
pharmaceutical works polpharma sa, poland - ciprofloksacīns - apvalkotā tablete - 500 mg
nelladel apvalkotās tabletes
idelyn s.r.o., czech republic - hyperici trūkumzālītes ekstraktu sausas, cimicifugae rhizomae sausā ekstrakta - apvalkotā tablete - 300 mg/6,4 mg
ciprofloxacin sandoz 500 mg apvalkotās tabletes
sandoz d.d., slovenia - ciprofloksacīns - apvalkotā tablete - 500 mg
leflunomide sandoz 20 mg apvalkotās tabletes
sandoz d.d., slovenia - leflunomīds - apvalkotā tablete - 20 mg
mektovi
pierre fabre medicament - binimetinib - melanoma - antineoplastiski līdzekļi - binimetinib kopā ar encorafenib ir norādīts ārstēšanai pieaugušiem pacientiem ar unresectable vai metastātiska melanoma ar braf v600 mutācijas.
calvinia 10 mg mutē disperģējamās tabletes
gedeon richter plc., hungary - rizatriptāns - mutē disperģējamā tablete - 10 mg
ciprofloxacin norameda 2 mg/ml šķīdums infūzijām
norameda uab, lithuania - ciprofloksacīns - Šķīdums infūzijām - 2 mg/ml
ozawade
bioprojet pharma - pitolisant - sleep apnea, obstructive - other nervous system drugs - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
teriflunomide accord
accord healthcare s.l.u. - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - immunosuppressants, selektīvi immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).